Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03478761 · ClinicalTrials.gov registry record
24-Hydroxylase Deficiency and CYP24A1 Mutation Patient Registry
A clinical trial of 24-hydroxylase Deficiency, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT03478761: Recruiting study of 24-hydroxylase Deficiency, sponsored by Mayo Clinic.
NCT03478761 is a study of 24-hydroxylase Deficiency that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 600 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03478761, a study of 24-hydroxylase Deficiency, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
You are being asked to take part in this research registry because you or your family member is suspected to have a 24-hydroxylase deficiency.
Primary Outcome
This patient registry will expand knowledge of the clinical expression of this disease by systematically accumulating and analyzing information regarding a larger number of patients than have been studied to date.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2017-10-19 |
| Est. Completion | 2030-12 |
What NCT03478761 shows while recruiting
NCT03478761 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with 24-hydroxylase Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT03478761 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03478761 about?
NCT03478761 is a clinical study titled "24-Hydroxylase Deficiency and CYP24A1 Mutation Patient Registry". You are being asked to take part in this research registry because you or your family member is suspected to have a 24-hydroxylase deficiency.
What is the current status of trial NCT03478761?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2017-10-19. Estimated completion is 2030-12.
What conditions does trial NCT03478761 study?
This clinical trial studies the following conditions: 24-hydroxylase Deficiency.
Who is sponsoring clinical trial NCT03478761?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03478761 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI